Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Karyopharm Therapeutics Inc. filings document the formal disclosures of a commercial-stage oncology company centered on XPOVIO (selinexor), clinical development programs, financing arrangements, and governance matters. Form 8-K reports include operating and financial results, preliminary revenue and liquidity disclosures, clinical and regulatory updates, material agreements, and capital-structure events.
The company’s SEC record also includes proxy materials for annual and special stockholder meetings, director elections, executive compensation, shareholder voting matters, and amendments to authorized share capacity. Additional filings describe private placements, common stock and warrant structures, sales under equity offering arrangements, and amendments to credit and guaranty agreements, including covenant and liquidity terms.
Adage Capital Management and affiliated reporting persons disclose beneficial ownership of 1,821,736 shares of Karyopharm Therapeutics common stock, representing 8.08% of the class. This percentage is calculated on an aggregate of 22,543,316 shares outstanding as of March 26, 2026 and assumes exercise of warrants exercisable for 15,414 shares held by Adage Capital Partners, L.P.
The filing attributes shared voting and shared dispositive power for the reported shares to the reporting persons and lists the reporting entities and individuals (Adage Capital Management, L.P.; Robert Atchinson; Phillip Gross) with their Boston business address. Signatures are dated May 13, 2026.
The Goldman Sachs Group, Inc. filed a Schedule 13G reporting shared voting and dispositive power over 991,363.52 shares of THERAPEUTICS INC. (CUSIP 48576U205) representing 5.1% of the class as of 03/31/2026.
The filing is a joint disclosure with Goldman Sachs & Co. LLC and includes a Joint Filing Agreement plus exhibits describing the parent/subsidiary reporting structure and customary disclaimers about client accounts.
Karyopharm Therapeutics Inc. ownership update: Opaleye entities report beneficial ownership of 619,089 shares of common stock issuable upon exercise of warrants, immediately exercisable, representing 2.67% of the class as of March 31, 2026. The percentage is calculated using 22,543,316 shares outstanding as of March 26, 2026 plus the shares issuable upon exercise. The statement is filed by Opaleye Management Inc., Opaleye, L.P., and James Silverman with respect to warrants directly held by the Fund.
Karyopharm Therapeutics Inc. filed a registration statement to register the resale of up to 8,843,036 shares of its common stock. The shares consist of 1,030,354 outstanding shares, 3,391,164 shares issuable upon exercise of pre-funded warrants and 4,421,518 shares issuable upon exercise of warrants. The company will receive no proceeds from resale; it agreed to pay registration expenses pursuant to a registration rights agreement related to a March 2026 private placement that generated approximately $30 million in gross proceeds. The prospectus discloses a 9.99% beneficial ownership limitation on warrant exercises and describes distribution methods including ordinary brokerage transactions, block trades and privately negotiated sales.
Karyopharm Therapeutics Inc. filed a shelf registration on Form S-3 to offer up to $400,000,000 of securities, including debt, common stock, preferred stock, units and warrants. The filing includes an at-the-market sales agreement with Jefferies to sell up to $100,000,000 of common stock from time to time. The prospectus describes general terms and states proceeds will be used for general corporate purposes. The document incorporates prior SEC reports by reference and discloses an Ernst & Young LLP audit opinion noting an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern.
Karyopharm Therapeutics EVP & Chief Medical Officer Reshma Rangwala reported a small, non-discretionary sale of common stock tied to taxes on vested equity. On April 21, 2026, a broker-assisted sale of 449 shares of common stock was executed at $8.94 per share.
According to the disclosure, this trade was carried out under a durable automatic sale instruction plan adopted on April 4, 2022 and was used to satisfy withholding tax liability from the vesting of restricted stock units. After this transaction, Rangwala directly holds 56,290 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. ownership update: three affiliated Millennium entities and Israel A. Englander report shared beneficial interests in common stock as of 03/31/2026. Integrated Core Strategies (US) LLC reports 423,982 shares (1.9%); Millennium Management LLC, Millennium Group Management LLC and Mr. Englander each report 511,571 shares (2.3%). The filing states these holdings are subject to shared voting and dispositive power and includes a joint filing agreement dated April 10, 2026.
Karyopharm Therapeutics is asking stockholders to vote at its 2026 annual meeting, to be held virtually on May 21, 2026 at 9:00 a.m. Eastern Time. Stockholders will elect two Class I directors, Barry E. Greene and Christy J. Oliger, for terms expiring at the 2029 meeting.
They will also vote on amendments to increase shares available under the 2022 Equity Incentive Plan by 3,000,000 shares and under the Amended & Restated 2013 Employee Stock Purchase Plan by 1,400,000 shares, an advisory say‑on‑pay proposal, and ratification of Ernst & Young LLP as independent auditor for 2026.
RA Capital Management and affiliated reporting persons reported beneficial ownership of 2,078,913 shares of Karyopharm Therapeutics common stock, representing 9.99% of the class.
The filing states the Fund directly holds 1,917,354 shares, pre-funded warrants exercisable for 3,391,164 shares, and warrants exercisable for 4,421,518 shares. The filing cites 19,618,032 shares outstanding as of March 23, 2026 and references a private placement of 1,030,354 shares that closed March 26, 2026. The Warrants include "Beneficial Ownership Blockers" that limit exercise to prevent ownership above 9.99%.